ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1254

Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Abstract Number: 1255

Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Abstract Number: 1256

Self-esteem and Body Image of Young People with Rheumatic Diseases: A Systematic Review
Abstract Number: 1257

The Psychological Experience of Work for People with Inflammatory Arthritis (IA)
Abstract Number: 1258

“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis
Abstract Number: 1259

Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases
Abstract Number: 1260

Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis
Abstract Number: 1261

Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients
Abstract Number: 1262

“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches
Abstract Number: 1263

Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases
Abstract Number: 1264

Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Abstract Number: 1265

Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Abstract Number: 1266

The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis
Abstract Number: 1267

Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Abstract Number: 1268

Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].